On the Cusp of Tackling One of the Greatest Healthcare Issues – Paralysis
INTERVIEW ON THE PRICE OF BUSINESS SHOW, MEDIA PARTNER OF THIS SITE.
Recently Kevin Price, Host of the nationally syndicated Price of Business Show, interviewed Bill Radvak.
Imagine a time when paralyzed people can become fully mobile or when people with neurodegenerative diseases finally have access to a drug that promotes repair and improves function?
Canadian biopharma entrepreneur, Bill Radvak, Interim CEO & Co-Founder NervGen Pharma Corp., a publicly traded (TSX-V: NGEN, OTCQX: NGENF) clinical stage biotech company dedicated to dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease, will discuss the company’s uplifting progress with human subjects with Kevin Price, host of the nationally syndicated Price of Business radio show, as the company gears up to complete a Phase 1 study with NVG-291, a first-in-class neuroreparative drug for the treatment of nervous system damage and discusss NervGen’s clinical trial plans with NVG-291 and spinal cord injury, Alzheimer’s and multiple sclerosis.
“Specifically, our company’s mission is to enable the body’s innate processes, such as neuroplasticity, axonal regeneration and remyelination, to repair damage to the nervous system, including damage from a spinal cord injury (SCI) or a traumatic brain injury (TBI),” says Radvak, who co-founded the company with Dr. Harold Punnett in 2018. “Target indications address significant unmet needs in spinal cord injury (SCI), Alzheimer’s, multiple sclerosis and stroke.” For more information, visit: https://nervgen.com/
Additional background
- An article in The Daily Mail reported that “the drug, codenamed NVG-291, works by removing a natural barrier in the body that prevents nerve cells from repairing.”
- Mother nature evolved a system that can’t repair what is arguably the most important part of ourselves, as without our nervous system, we are nothing — we can’t move, we can’t feel, we can’t think or heal from damage to the central nervous system (CNS).
- Editorial in New Scientist relays that, “the experimental drug (NVG-291) targets the ‘stickiness that can prevent injured brain tissue from functioning as it should.”
- On the National Defense Radio Show, hosted by Randy Miller, Radvak discussed how veterans are suffering from Traumatic Brain Injury (TBI) and Spinal Cord Injury (SCI) and what NervGen is doing to change their lives.
- The story of NervGen’s origins as ‘a story of tragedy, hope, and a dream, and one for which the end is yet to be written’ is featured in a newly published book by UK business author, Jan Cavelle.
- Radvak’s new article on ‘medical innovations advancing from the battlefield to mainstream medicine to aid military veterans with SCI and TBI injuries,’ highlights the next frontier of biopharma medicine.
- NVG-291 is a first-in-class drug candidate wrapping up its Phase 1 clinical trial in healthy volunteers to evaluate safety, tolerability and metabolism. After completing Phase 1 clinical trial, NervGen plans to initiate Phase 1b/2 clinical trials in spinal cord injury and Alzheimer’s, and a Phase 2 in multiple sclerosis.
Check out more national news stories here.
LISTEN TO THE INTERVIEW IN ITS ENTIRETY HERE:
The Price of Business is one of the longest running shows of its kind in the country and is in markets coast to coast. The Host, Kevin Price, is a multi-award winning author, broadcast journalist, and syndicated columnist. Learn more about the show and its digital partners at www.PriceofBusiness.com (scroll down to the bottom of the page).
About Author
